Teva Pharmaceutical Industries Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard D. Francis
- Full Time Employees
- 32,008
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 124 Dvora Hanevi’a Street Tel Aviv TA Israel 6944020
- IPO Date
- Feb 16, 1982
- CIK
- 0000818686
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited, an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Petah Tikva, Israel, develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products worldwide across more than 60 countries with manufacturing facilities in Israel, North America, Europe, Australia and South America; core generic offerings span various dosage forms including tablets, capsules, ointments, creams, liquids, injectables and inhalants for therapeutic areas such as pain management, cardiovascular diseases, infectious diseases, central nervous system disorders, respiratory conditions, oncology and generics leadership in complex products; key innovative medicines include AUSTEDO (deutetrabenazine) for chorea in Huntington's disease and tardive dyskinesia, AJOVY (fremanezumab) for migraine prevention, UZEDY for schizophrenia, Copaxone for multiple sclerosis and a pipeline featuring olanzapine LAI, duvakitug for inflammatory bowel disease, DARI asthma inhaler, emrusolmin and TEV-56278 (anti-PD1-IL2 ATTENUKINE) for oncology. The company operates in segments including generics and biosimilars targeting healthcare providers, pharmacies and hospitals globally, with a focus on neuroscience, immunology, respiratory diseases and pain management customer bases. Teva advances its Pivot to Growth strategy, launched in 2023 and accelerated in 2025, to build a greater than $5 billion innovative medicines franchise by 2030 through robust late-stage pipeline execution, 25 to 27 biosimilar launches by 2027 including eculizumab-aagh with Samsung Bioepis and PONLIMSI/DEGEVMA denosumab biosimilars approved in Europe; recent strategic partnerships encompass a June 2025 collaboration with Fosun Pharma for TEV-56278 development in Asia, a prior alliance with Sanofi for TEV-574 anti-TL1A in inflammatory bowel disease, and the November 2025 launch of Teva Rise open innovation platform for AI, digital health and manufacturing advancements; ongoing efforts include divestiture of its API business TAPI announced in 2024, eleven consecutive quarters of revenue growth as of Q3 2025 driven by 33% innovative portfolio increase in local currency, reaffirmed 2027 targets of 30% operating profit margin, over $2.7 billion free cash flow and $2.5 billion Estero revenues with peak sales exceeding $3 billion, alongside credit upgrades reflecting debt reduction and operational enhancements.
Company News
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Outperforming Pharma Stock Still Has Upside Potential
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
Teva's immune disorder drug meets main goal in mid-stage trial
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Settles Patent Litigation with Teva
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Humana agrees not to reference Teva's Israel ties at US drug trial